Biotech news on June 23, 2026

1. 0122:00 UTC

   Kennedy says US should lead in medical research and innovation

   6 outlets · first: abc6onyourside.com Clinical trial

   Machine summary Kennedy said HHS is taking action to increase America's clinical research enterprise, including FDA steps he wrote could reduce development timelines by 6 to 12 months.

   1. Kennedy said America should be leading in innovation regarding medicine, according to the reports.

   Reported by abc6onyourside.com, abc3340.com, Katv, Wgxa, foxreno.com and kcby.com.

2. 0213:45 UTC

   Lexaria says animal study GLP-1-A26-1 began dosing on schedule

   2 outlets · first: newjerseytelegraph.com (Big News Network) Clinical trial

   Machine summary The company said the study evaluates DehydraTECH-semaglutide and DehydraTECH-CBD compositions, including alternative formulations to SNAC, and that it has filed 3 new patent applications in this area.

   1. Lexaria said one novel objective is to evaluate alternative formulations to SNAC, which it said is currently in use by Novo Nordisk with oral Rybelsus and Wegovy tablet products.
   2. Lexaria said it has already filed 3 new patent applications anticipating its latest technological improvements in this area.

   Reported by newjerseytelegraph.com (Big News Network), hawaiitelegraph.com (Big News Network), finanznachrichten.de and californiatelegraph.com (Big News Network).

   • Novo Nordisk
   • Semaglutide
   • Wegovy
   • DehydraTECH
   • Lexaria Bioscience Corp.
   • GLP-1-A26-1

3. 0312:45 UTC

   Cognivia-Mayo Collaboration Targets 3 Behavioral Drivers to Improve Trial Retention

   2 outlets · first: Pr Newswire Clinical trial Mostly press releases

   Machine summary Cognivia announced it is teaming with Mayo Clinic to advance behavioral intelligence in clinical care and clinical research, starting with missed appointments, non-adherence, and retention in clinical trials. The announcement says the collaboration will additionally address dropout from clinical trials; Mayo Clinic holds a financial stake in the referenced technology and will direct all revenue it gets toward its not-for-profit mission.

   1. Cognivia and Mayo Clinic announced a collaboration on June 23, 2026, to advance behavioral intelligence in clinical research and clinical care.
   2. The collaboration will initially focus on three behavioral drivers: non-adherence, missed appointments, and clinical trial dropout.
   3. Cognivia's platform is designed to make patient behavior measurable and actionable, enabling earlier identification of behavioral risk.

   Reported by Pr Newswire and finanznachrichten.de.

   • Mayo Clinic
   • Cognivia

4. 0423:00 UTC

   China clinical drug trial registrations hit record in 2025, regulator says

   1 outlet · first: scmp.com Clinical trial

   Machine summary China's National Medical Products Administration reported 5,215 clinical drug trials registered in 2025, more than double the 2020 figure, according to a report released Monday.

   Reported by scmp.com.

   • National Medical Products Administration (NMPA)

5. 0519:15 UTC

   DOJ announces over 450 charged over alleged healthcare fraud

   1 outlet · first: iHeartRadio

   Machine summary Acting Attorney General Todd Blanche said the alleged fraud amounts to more than $6.5 billion.

   1. The DOJ announced charges against over 450 defendants across 45 U.S. states and territories, the reports said.
   2. Acting Attorney General Todd Blanche said the alleged fraud amounts to more than $6.5 billion, according to the reports.
   3. According to the reports, those charged include 100 individuals accused of Medicaid fraud and 90 medical professionals.
   4. The reports said the DOJ established a Health Care Fraud Data Fusion Center.

   Reported by iHeartRadio.

   • Todd Blanche
   • Health Care Fraud Data Fusion Center

6. 0600:45 UTC

   AnHorn says AH-008 gets FDA IND clearance, Taiwan CDE index case designation

   1 outlet · first: Pr Newswire Clinical trial Mostly press releases

   Machine summary AnHorn Medicines said its lead neuroprotective candidate AH-008, being developed to prevent chemotherapy-induced peripheral neuropathy, received Investigational New Drug clearance from the U.S. Food and Drug Administration and Index Case designation from the Taiwan Center for Drug Evaluation. The company said the FDA clearance authorizes AH-008 to advance into human clinical trials.

   1. AH-008 is in development to prevent chemotherapy-induced peripheral neuropathy (CIPN), AnHorn Medicines said.
   2. AnHorn said the U.S. FDA granted Investigational New Drug clearance for AH-008.
   3. AnHorn said the Taiwan Center for Drug Evaluation granted Index Case designation for AH-008.
   4. The FDA's IND clearance authorizes AH-008 to move forward into human clinical trials, according to AnHorn.
   5. AnHorn said no approved therapies currently exist to prevent CIPN.

   Reported by Pr Newswire.

   • AH-008
   • AnHorn Medicines
   • Taiwan CDE

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.